satralizumab
Sign in to saveAlso known as sapelizumab, SA237
Satralizumab, sold under the brand name Enspryng, is a humanized monoclonal antibody medication that is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease. The drug is being developed by Chugai Pharmaceutical, a subsidiary of Roche.
Wikidata facts
- Instance of
- medication
Show 1 more fact
- medical condition treated
- neuromyelitis optica
Sources (1)
via Wikidata · CC0
~6 min read
Encyclopedic overview
11 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Pharmacology
- Mechanism of action
- Efficacy
- Society and culture
- Legal status
- Names
- References
- External links
Satralizumab, sold under the brand name Enspryng, is a humanized monoclonal antibody medication that is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease. The drug is being developed by Chugai Pharmaceutical, a subsidiary of Roche.
The most common side effects include the common cold (nasopharyngitis), headache, upper respiratory tract infection, inflammation of the lining of the stomach, rash, joint pain, extremity pain, fatigue and nausea.
Excerpted from Wikipedia’s “satralizumab” article, available under the CC BY-SA 4.0 licence.